| ALPAX | VIVIX | ALPAX / VIVIX | |
| Total Expense Ratio | 1.09 | 0.04 | 2,725% |
| Annual Report Gross Expense Ratio | 1.09 | 0.04 | 2,725% |
| Fund Existence | 25 years | 27 years | - |
| Gain YTD | 13.879 | 11.991 | 116% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 2500 | 5000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.67B | 208B | 1% |
| Annual Yield % from dividends | 1.33 | 2.10 | 63% |
| Returns for 1 year | 1.92 | 6.69 | 29% |
| Returns for 3 years | 18.06 | 33.49 | 54% |
| Returns for 5 years | 13.93 | 66.36 | 21% |
| Returns for 10 years | 54.07 | 134.98 | 40% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| KCEIX | 12.56 | 0.06 | +0.48% |
| Knights of Columbus Long/Short Eq I | |||
| AEUDX | 9.07 | 0.04 | +0.44% |
| American Century Equity Income R6 | |||
| LEAIX | 15.92 | 0.04 | +0.25% |
| Lazard Emerging Markets Eq Advtg Instl | |||
| FBTCX | 28.38 | N/A | N/A |
| Fidelity Advisor Biotechnology C | |||
| ALCBX | 13.41 | N/A | N/A |
| ALPS/Smith Balanced Opportunity C | |||